It was announced this Monday that Fulcrum Therapeutics, a Phase 1 biotech developing therapies based on gene regulation for rare diseases, announced terms for its initial public offering (IPO), aka its stock market launch.

This is great news; a biotech company centered on rare disease treatments going public means better financial viability!

We’ve previously written about Fulcrum Therapeutics and their efforts for facioscapulohumeral muscular dystrophy (FSHD) drug losmapimod treatment. 

The Massachussets-based company plans to raise $77 million by offering 4.5 million shares at a price range of $16 to $18.

So any stock market players out there, perhaps you’ll get a piece of the pie!

Fulcrum Therapeutics was founded in 2016 and it plans to list on the Nasdaq under the symbol FULC. It is expected to price during the week of July 15, 2019.

This brings hope that the business of treating and researching rare diseases can be come more and more mainstream. This move is one big step forward!

What are your thoughts? Share your stories, thoughts, and hopes with the Patient Worthy community!